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Abstract 
Oxidative stress is a key mechanism causing Diabetic Nephropathy (DN). Acidic fibroblast 
growth factor (aFGF) is known to confer protection from oxidative stress. However, it 
also has significant angiogenic activity. Hence, we have generated a mutated human 
acidic FGF (maFGF), with intact antioxidant properties but devoid of angiogenic 
activities. Recent evidence shows that maFGF treatment prevented diabetic 
cardiomyopathy and further in vitro studies suggest that this prevention is mediated by 
suppression of cardiac oxidative stress, hypertrophy and fibrosis. We hypothesized that 
maFGF treatment has a protective effect in DN.  
We show that maFGF treatment did not affect body weight and blood sugar levels in a 
type 1 diabetic mouse model. However maFGF prevented renal functional alterations in 
diabetes and decreased renal hypertrophy following long-term diabetes. maFGF also 
prevented diabetes–induced DNA damage, upregulation of angiotensinogen, oxidative 
stress marker heme oxygenase 1, and alteration of endothelial nitric oxide synthase 
(eNOS). Surprisingly, it failed to prevent upregulation of the fibrogenic cytokine 
transforming growth factor β1 mRNA expression. However, long term administration of 
maFGF partially prevented diabetes-induced extracellular matrix proteins accumulation. 
Further analyses showed similar results in high glucose-induced alterations in podocytes 
and microvascular endothelial cells. Likewise, maFGF showed prevention of diabetes- 
induced decreased nitric oxide (NO) production and apoptosis in vivo and in vitro. These 
results were consistent with the prevention of long term diabetes- induced down 
regulation of eNOS enzyme. Data from these experiments suggest that the preventative 
effects of maFGF treatment in DN are probably via alteration of NO production, and 
indicate a potential therapeutic role of maFGF in DN. 
 
Keywords: modified acidic FGF, acidic FGF, diabetic nephropathy, oxidative stress, nitric 
oxide. 
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1.1 Diabetes Mellitus 
Diabetes Mellitus (DM) is a metabolic disorder that exhibits a defective or deficient 
insulin secretory response, glucose underutilization, and hyperglycemia 1. It is classified 
in two major types according to its etiology: type 1 DM (insulin dependent) and type 2 
DM (non insulin dependent). The etiology of type 1 DM is associated with absolute lack 
of insulin, which is caused by a reduction of β cells in the pancreas due to autoimmune 
reactions. It is also called juvenile diabetes as the onset of this disease is before 20 years 
of age. Alternatively, type 2 DM is characterized by insulin resistance (that happens 
when cells fail to use insulin properly) and sometimes is combined with an absolute lack 
of insulin, mainly when the disease is advanced. This is the result of the failure of 
pancreatic beta cells over time to secrete more insulin to compensate hyperglycemia in 
the insulin-resistant state 2. Type 2 DM is associated with overweight or obesity and 
usually appears after 30 years of age, although the trend of younger people with this 
disease is increasing 1, 2, 3. There are other types of diabetes namely gestational diabetes 
that occurs when pregnant women develop a high blood glucose level without having a 
previous history of diabetes. This third type of diabetes usually resolves after the birth of 
the baby 1. 
The treatment strategy for the various types of diabetes differs, however monitoring 
and control of blood glucose levels, keeping a healthy diet and regular physical activity is 
equally important. In the case of type 1 DM, insulin injections are required and islet cell 
transplant can be performed to patients with specific requirements. Various medications 
and/or insulin can be used to treat type 2 or gestational DM: antihyperglycemic, 
hypoglycemic agents and insulin sensitizers such as the family of Biguanide (metformin), 
sulphonylureas (glibenclamide), Thiazolidinediones (pioglitazones) and others 3. 
In type 1 and type 2 diabetes the net effect is a chronic disorder of carbohydrate, fat and 
protein metabolism with resulting chronic complications affecting the blood vessels, 
kidneys, eyes and nerves 1. These secondary complications, which include coronary and 
cerebrovascular disorders, peripheral arterial disease, nephropathy and retinopathy, are 
the main cause of the increased morbidity and mortality in the diabetic population. 
3 
 
 
Hence, the study of the molecular pathophysiology of diabetes complications can bring 
up insights for potential treatments to manage these complications. 
1.2 Epidemiology  
Diabetes Mellitus is one of the fastest-growing health issues in the world, affecting 
around 387 million people in the planet 4. As a consequence of a life-style consisting in 
lack of exercise, an unhealthy diet and overweight/obesity, DM is reaching epidemic 
proportion in some regions. North America and the Caribbean is the region with higher 
prevalence with an estimate of 39 million people with this disease. 
According to the American Diabetes Association (ADA), the prevalence of diabetic and 
prediabetic cases in the United States has increased since 2010 and diabetes remained 
the seventh cause of death by the same year 5. In Canada, the overall prevalence of 
diabetes has increased gradually although incidence has been stable in the last decade 
6). The relative increase in prevalence accounts mainly for Canadians in the working age 
group and it is associated with overweight and obesity. This causes a burden to the 
health care system as individuals with diabetes are estimated to create three to four 
times more health care expenses than individuals without diabetes 5, 6. Some examples 
include the increased risk of hospitalization with cardiovascular disease (over 3 times), 
end- stage renal disease (12 times) and non-traumatic lower limb amputations (20 
times) of diabetic individuals compared to non diabetic population 5, 6.   
Diabetic nephropathy (DN) is one of the significant long-term complications in terms of 
morbidity and mortality for individual patients with diabetes. It is estimated that about 
25-40% of diabetic patients develop DN within 20-25 years of the onset of diabetes 7. In 
fact, diabetes is responsible for 30-40% of all end-stage renal diseases in North America 
8, 9.  
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1.3 Diabetes Nephropathy and pathophysiologic changes  
Diabetic nephropathy is a clinical syndrome characterized by the following 10:  
 Persistent albuminuria (>300 mg/d or >200 μg/min)  
 Progressive decline in the glomerular filtration rate (GFR) 
 Elevated arterial blood pressure  
At the tissue level, various cell types are involved in DN. They include glomerular 
podocytes, mesangial cells and endothelial cells, tubular epithelium, and interstitial 
fibroblasts 9, 11. However, similar to the other diabetic complications, DN is essentially a 
microvascular disease in which endothelial dysfunction serves as a key event in its 
development and progression. 
 Additionally, DN develops as a result of the confluence of hemodynamic and metabolic 
perturbations 9, 12, 13. The pathophysiologic changes comprise hyperfiltration, 
hyperperfusion and microalbuminuria in the very early stages followed by worsening of 
renal functions. This is linked with diffuse thickening of the glomerular and tubular 
basement membranes, as well as mesangial matrix and tubule-interstitial compartment 
expansion caused by increased deposition of extracellular matrix proteins and mesangial 
cell hypertrophy. The progressive expansion of the mesangium in the later stages 
restricts the capillary surface available for filtration and, as a consequence, the 
glomerular filtration rate falls. In addition, another pathologic correlates are glomerular 
podocyte alteration and loss. This is exhibited through effacement of foot processes and 
decreased number of podocytes (detachment of podocytes from the glomerular 
membrane) due to apoptosis. These changes ultimately progress to proteinuria, 
glomerulosclerosis and tubulointerstitial fibrosis 9, 11-14. 
1.4 Pathophysiologic mechanisms in DN 
Similar to the other microvascular complications of diabetes , hyperglycemia is the major 
factor which causes damage to the discussed cell types by increasing the production of 
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reactive oxygen species (ROS) 9, 14, 15. Moreover, DN is thought to result from 
interactions involving metabolic and hemodynamic factors 9, 13. Hyperglycemia increases 
superoxide production by the mitochondrial electron transport chain. Increased ROS 
inhibits glycolysis by interfering with the activity of the enzyme glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) impelling glucose to other pathways which also 
induce oxidative stress 14. These specific glucose dependent metabolic pathways are 
activated within the endothelial cells and include increased flux of polyols and 
hexosamines, increase activity of protein kinase C (PKC) and generation of advanced 
glycation end products (AGE).  As a result, other cellular events triggered are increased 
activity of transforming growth factor β (TGF-β)- Smad-MAPK and G-proteins, altered 
expression of cyclin kinases and their inhibitors, and of matrix degrading enzymes and 
their inhibitors 9, 11, 12.  
Hemodynamic factors implicated in DN include elevation of systemic and 
intraglomerular pressure and activation of various vasoactive factors pathways including 
the renin-angiotensin system and endothelins 7, 12, 13. The altered hemodynamic changes 
act in concert with metabolic pathways to activate intracellular second messengers 
which affect gene expression. Some of the consequences are increased prosclerotic 
cytokine TGF-β1, transcription factors such as NF- κB that activates local inflammatory 
responses and various growth factors such as the permeability enhancing VEGF. 
Ultimately, these molecular mechanisms lead to the progression of the functional and 
structural changes that lead to end stage renal failure 9, 11, 14 (Figure 1.1).  
1.4.1 Oxidative stress in DN 
Oxidative stress occurs when the amount of reactive oxygen species (ROS) and reactive 
nitrogen species (RNS) are more than the defensive system can remove 15, 16. In DN, 
there are a number of enzymatic and non enzymatic sources of ROS including auto 
oxidation of glucose, transition metal-catalyzed Fenton reactions, advanced glycation 
end products formation, polyol pathway flux, mitochondrial respiratory chain  
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Figure 1.1 Scheme of the Pathophysiological mechanisms of DN. Metabolic and 
hemodynamic processes are induced by hyperglycemia and act in concert activating 
different pathways with altered expression of genes and cellular dysfunction. Oxidative 
stress from ROS and RNS generation is enhanced by hyperglycemia-induced metabolic 
and hemodynamic processes and is important for the formation of mediators causing 
structural alterations and functional damage (Figure adapted from reference # 13). 
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deficiencies, xanthine oxidase activity, peroxidases, nitric oxide synthase and (NADPH) 
oxidase 15. The mitochondrial respiratory chain is thought to be a major source of excess 
ROS in diabetes in response to hyperglycemia and a key initiator for the pathogenic 
pathways 14, 15. Furthermore, a number of functional enzymes within the mitochondria 
are particularly susceptible to ROS mediated damage, leading to altered ATP synthesis, 
cellular Ca2+ dysregulation, and induction of mitochondrial permeability transition, all of 
which predispose the cell to necrosis or apoptosis 15.  
In addition, overproduction of superoxide has shown to be associated with endothelial 
dysfunction by activating proinflammatory signals and inactivating important enzymes 
involved in vascular homeostasis such as endothelial Nitric Oxide Synthase (eNOS) 17, 18. 
Therefore, oxidative stress suppresses Nitric Oxide (NO) bioavailability which increase 
generation of ROS and lead to oxidative damage to lipids, proteins, aminoacids and DNA 
17. This decreased NO bioactivity is also thought to be due to quenching by increased 
ROS production. NO is inactivated through its reaction with ROS to form peroxynitrite 
(ONOO-) which is toxic and exhibits direct oxidative reactivity. Hence, the rate of NO 
production and its reactivity relies on the rates of ROS generation in the tissues 17. 
1.4.2 Nitric Oxide and endothelial dysfunction in DN 
Nitric Oxide is considered the single most important factor for maintaining vascular 
endothelial function and vascular tone relaxation 17, 19. Several studies have shown that 
NO produced by endothelial cells through eNOS plays a major role for maintaining 
vascular function and homeostasis, and that decreased NO production and 
bioavailability in effect contribute to endothelial dysfunction in diabetes 17, 20-21. 
Moreover, the development and progression of DN is associated with alterations in 
eNOS expression and activity 17, 22. The fact that lack of eNOS can contribute to both 
glomerular and tubulointerstitial fibrosis suggests that disruption of NO signaling in the 
kidney may be a major factor in the development of DN 17. 
Nitric Oxide is a gaseous free radical molecule which is synthesized by the action of the 
enzymes Nitric Oxide Synthase (NOS) using as substrate L-arginine and yielding L-
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citrulline. It plays several physiological roles in the kidney, including control of renal and 
glomerular hemodynamics, promoting natriuresis and diuresis, and renal adaptation to 
dietary salt intake 23. There are three different isoforms of NOS: endothelial (eNOS), 
neuronal (nNOS) and inducible (iNOS) enzymes, and the three are present in the kidneys 
20, 21.  The eNOS isoform was shown to be the major NOS enzyme in renal vasculature, 
nNOS is more abundant in the macula densa whereas iNOS is weakly expressed in the 
kidney 23, 24.  
The eNOS enzyme is only fully functional in a dimeric form and the functional activity of 
the dimer depends on the level of tetrahydrobiopterin (BH4), a cofactor for NOS enzyme 
17, 21-25. Under physiological conditions eNOS exists as a dimer and produces NO but the 
enzyme reduces oxygen to superoxide anion when there is decreased availability of BH4. 
Additionally, the uncoupling of eNOS induced by oxidation of the enzyme zinc-thiolate 
cluster by small amounts of ONOO- decreases NO synthesis and increases superoxide 
anion production by the enzyme 17. Diabetes is associated with eNOS uncoupling and 
decreased BH4 levels due to its oxidation by ROS. This condition promotes further 
oxidative stress and decreased NO bioavailability 17, 25. Indeed, uncoupling of eNOS is 
one of the pathways identified as potentially major contributors of the pathogenesis of 
diabetic kidney disease 15. 
Dysregulation of NO has been described in patients with DN, including increased eNOS 
activity early after the onset of diabetes, with augmented basal NO release which might 
explain intrarenal vasodilation and hyperfiltration seen in this first stage. Prolonged 
diabetes is associated with downregulation of glomerular or renal eNOS expression 
which leads to NO deficiency that may facilitate the progression of DN 20, 21, 26. The other 
isoforms nNOS and iNOS are expressed variably in diabetic kidneys 24.  
Additionally, in vitro studies have evidenced that hyperglycemia reduces eNOS activity 
and/or NO bioavailability in endothelial cells leading to decreased endothelial cell 
survival and endothelial dysfunction 11, 19. Also, the combination of eNOS deficiency and 
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hyperglycemia leads to podocyte injury 26. In fact, eNOS deficiency by itself provokes 
profound effects on podocyte integrity and leads to albuminuria 12, 26. 
Increased evidence shows the cross-talk between glomerular endothelial cells and 
podocytes through the secretion of cytokines and growth factors. This cross-talk can 
influence the behaviour of the glomerular filtration membrane and the susceptibility for 
the development and progression of kidney disease 27. Indeed, there is evidence that the 
severity of DN lesions and renal function in type 1 diabetic patients is associated with 
reduction of glomerular endothelial cells fenestration and increase in podocyte 
detachment 28. 
Accordingly, the understanding of the mechanisms and mediators involved in the 
pathophysiology of DN including the communication between the cells in the kidney is 
an important action to tackle the development of new potential therapies in order to 
prevent early complications. 
1.5 Therapeutic strategies in DN 
The major therapeutic strategies involved in the management and prevention of DN 
have included intensified glycaemic control and antihypertensive agents particularly 
those which interrupt the renin-angiotensin system such as angiotensin receptor 
blockers (losartan or irbesartan) 12, 13. Recently, novel strategies have been under clinical 
investigations and include inhibitors of AGEs, inhibitors of metabolic pathways such as 
specific PKC isoforms or the enzyme aldose reductase, or inhibitors of vasoactive factors 
29. All of these targeted pathways seem to have a common mechanism as they are 
triggered by oxidative stress, and some contribute to enhance the oxidative stress inside 
the cells. It is predicted that multiple therapies will be required to reduce the 
progression of DN.  
Considering that hyperglycemia-induced oxidative stress plays such an important role in 
the pathogenesis of diabetic complications, the investigation of new molecules with 
preventative effects or protective action against oxidative stress may be a wise adjuvant 
therapy required to further optimize renoprotection in diabetes. Some molecules that 
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have conferred protection to the cells from oxidative damage are the acidic and basic 
fibroblast growth factors (aFGF, bFGF). 
1.6 The acidic and basic Fibroblast Growth Factors  
The aFGF (or FGF1) and bFGF (or FGF2) belong to a large family of heparin-binding 
growth factors (polypeptides) that has 23 members to date. Both are considered 
prototype members of this family and are closely related molecules: they have 53 % 
sequence homology, interact with the same receptor and posses mitogenic properties 
toward fibroblasts and endothelial cells 30, 31, 32. They can affect differentiation, 
migration and survival of many cell types, playing an important role in the control of 
nervous system, wound healing and in tumor angiogenesis. FGFs mediate their cellular 
responses by binding to and activating a family of 4 receptor tyrosine kinases. These 
peptides are located in the ECM, bind to heparin or heparan-sulfate proteoglycans which 
act as an accessory molecule that regulate FGF-binding and the activation of the 
occupied signaling receptors 30-33.  
The four isoforms of the receptors (FGFR1-4), encoded in four different genes, are 
generated by alternative splicing of FGFR transcripts 33. The activation of these receptors 
initiates further downstream signaling by mitogen-activated protein kinase (MAPK), 
phosphatidilinositol-3 kinase (PI-3K) and phospholipase C 31-33. This signalling is mediated 
via direct recruitment of signalling proteins that bind to tyrosine auto-phosphorylation 
sites on the activated receptor and, via closely linked docking proteins (that become 
tyrosine phosphorylated in response to FGF-stimulation), form a complex with additional 
complement of signaling proteins 33(Figure 1.2). The receptors seem to mediate 
activation of the same targets and differ only in the strength of their tyrosine kinase 
activity. Furthermore, they have different abilities to mediate the translocation of 
external FGF to the cytoplasm and nucleus, which appears to be due to variation in their 
C-terminal tail. As a result, FGFR1 and FGFR4 are able to mediate translocation whereas 
FGFR2 and FGFR3 lack this ability 34. It has been shown that this translocation to the 
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nucleus determines the mitogenic activity of FGFs since it is a necessary condition to 
activate DNA synthesis and proliferation 35, 36 (Figure1.2).    
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Figure 1.2 Diagram depicting signaling pathways downstream of FGFR-1 upon tyrosine 
phosphorylation. Besides the activation of the downstream signalling by MAPK 
(mitogen-activated protein kinase), PI-3K (phosphatidilinositide-3 kinase) and PKC 
(protein kinase C), the receptor complex is translocated to the nuclei for activation of 
DNA synthesis. This is thought to be a necessary condition to induce proliferation (Figure 
adapted from reference # 37). 
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Some studies show that FGFs interact with the FGFRs based on its tridimensional 
structure. The FGF residues interacting with the specific tyrosine kinases cluster in two 
separate patches of its three dimensional structure: recognition site 1 (RS1) which seems 
to be important for mitogenesis and recognition site 2 (RS2) that seems to be involved in 
vasodilatory and ischemic protective actions and have a less important rate in the 
mitogenic activity of the protein 38.  
FGF has been found to be in an inactive form in the cytoplasm and is activated by cell 
injury 33. It is produced by endothelial cells, fibroblasts, macrophages, smooth muscle 
cells, myoblasts, lens epithelial cells and osteoblasts 30, 33.  
1.6.1 The aFGF and bFGF as non-mitogenic and pleiotropic peptides 
FGFs are implicated in a wide range of pathological conditions such as tumorigenesis and 
metastasis, mainly due to its potent angiogenic activity. In the context of diabetic 
complications, bFGF has been reported to contribute to the glucose-induced vascular 
dysfunction 39, and is upregulated in diabetic retinopathy 40, 41, 42, 43, 44. Particularly in 
DN, there are reports of upregulated expression of bFGF with a good correlation to the 
degree of renal injury 32. Furthermore, it is known that bFGF is induced in human renal 
fibrosis (characteristic of DN) and induces proliferation in human renal fibroblasts after 
activation by TGF-β1 39. 
On the other hand, there is evidence of the survival effects of FGFs in the context of 
oxidative stress.  As these peptides are multifunctional, multiple studies are based on 
the nonmitogenic properties of FGFs in differentiated cells. In the retina, basic FGF has 
been found to augment endothelial cells’ resistance to oxidative stress 45 and improves 
recovery from ischemia and reperfusion injury in brain and kidney 46,47. In the heart, 
aFGF has attenuated tissue damage after myocardial ischemia followed by reperfusion 
48, and has shown protection on ischemic kidney, liver and gut injuries 49.  
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The FGFs can also produce vasoactive responses as confirmed in some studies where 
aFGF and bFGF were found to induce vasodilation in microvessels indicating that FGFs 
are able to stimulate endothelial NOS expression and subsequent synthesis of NO 50, 51, 
52. These results are evident not only in endothelial cells but in smooth muscle cells and 
some types of cancer cells, and may be associated with the survival actions of FGFs 51, 52, 
52, 53, 54. 
However such potential therapeutic applications have been limited due to the presence 
of the mitogenic property of these molecules. Hence, the use of a non-mitogenic form of 
FGF would potentially avoid undesirable proliferative effects observed with the native 
mitogenic proteins.  
1.6.2 The modified human aFGF 
Considering the various functions of FGFs, some modifications have been done to the 
native FGF molecule to uncouple the mitogenic activity from the vasodilatory and 
antiapoptotic actions 38, 47, 55, 56, 57, 58, 59, 60, 61. Although the primary translation product 
for aFGF is a 155 aminoacids protein, it could result in polypeptides of 134, 140 or 154 
residues due to specific proteolytic cleavages 62, 63 . Several studies have also been made 
with non mitogenic human acidic fibroblast growth factor (nhaFGF; nm-aFGF), 
recombinant human acidic FGF (FGF28-154) or modified human acidic FGF (maFGF), 
which are devoid of mitogenic activity and show potent antiapoptotic actions 38, 55, 57-61.  
The mutated aFGF has been generated by deleting the sequence of the first 27 
aminoacids near the NH2-terminus (FGF28-154) 57. This modification suggests that the 
lack of mitogenic activity of this polypeptide derives from the alteration of the RS1 
tridimensional structure. Moreover, this change is considered to confer instability to the 
maFGF to successfully interact with the receptor. This mutated domain has the role to 
maintain the structural integrity of aFGF required for optimal binding to and activation 
of the transmembrane receptor complex 38, 64. The truncated protein does not induce 
cell division even though it is recognized by the cell membrane receptor, triggers the 
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early mitogenic events, and retains the neuromodulatory, vasoactive, and cardio- and 
neuroprotective properties of the native full-length molecule 38. 
Recent studies using maFGF have shown cardiovascular protection from oxidative stress 
in vitro and in vivo 58 and protection from the cytotoxic effects of hydrogen peroxide 
treatment in cultured cardiomyocytes 59. The effects of ischemia/reperfusion- induced 
cardiac dysfunction and tissue damage were significantly attenuated in rats with in-vivo-
administered maFGF 48. Similar results were obtained in cerebral ischemia/reperfusion 
injury which was prevented by the same treatment 59. Oxygen free radicals generation is 
one of the mechanisms responsible for ischemia-reperfusion damage. Moreover, some 
of these studies reveal that the protective effect of the maFGF is associated with 
increase in cellular antioxidant activity 59, 60. Additionally, the maFGF treatment has 
shown prevention of diabetic cardiomyopathy 61. These latter results suggest protection 
through attenuation of cardiac oxidative stress, hypertrophy, and fibrosis.  
Since hyperglycemia-induced oxidative stress plays an important role in the 
pathogenesis of DN, we hypothesize that maFGF prevents kidney damage in DN.   
1.7 Rationale 
Metabolic changes in DN induce oxidative stress that triggers the activation of 
pathological mechanisms which lead to dysfunction of endothelial cells and glomerular 
visceral epithelial cells and eventually apoptosis.  Since modified aFGF is a non-mitogenic 
form of FGF that has antiapoptotic and protective actions from oxidative damage in 
tissues, it is possible that it could preserve the functionality of these cells and prevent or 
attenuate DN. The role of FGFs in diabetic nephropathy is not very well defined; hence 
the study of the maFGF could shed light to the possible ways that the native FGF exerts 
its actions in the metabolic changes in DN, granting further importance to this study. 
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1.8 Hypothesis 
The study is based on the hypothesis that modified aFGF treatment has a protective 
effect in diabetic nephropathy  
1.9 Specific Aims  
In order to test this hypothesis we formulated two specific aims. 
Aim 1: To investigate the effects of the maFGF on the biochemical, functional, and 
structural changes in the kidneys of type 1 diabetic mice. 
Aim 2:   To investigate the effects of the maFGF action in preventing glucose induced 
alterations in vitro. 
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Chapter 2: Materials and Methods 
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2.1 In vivo studies  
Groups of male FVB mice 8-10 weeks of age (Jackson Laboratory, Bar Harbor, Maine) 
received intraperitoneal injections of streptozotocin (STZ) (Sigma-Aldrich, St Louis, MO) 
dissolved in 0.1M sodium citrate (PH 4.5) at 50 mg/Kg body weight daily on 5 
consecutive days. Control mice received multiple injections of the same volume of 
sodium citrate buffer. Five days after the last injection of STZ, the blood glucose was 
measured. Mice with hyperglycemia (blood glucose levels 250 mM/dL) were defined as 
diabetic. Groups of control and diabetic mice were also subjected to treatment 
(intraperitoneal (IP) injections) with or without maFGF (produced by our collaborators 
using gene engineering) (10µg/Kg) every day for 1 month or for 6 months. Animals were 
monitored for body weight and blood glucose weekly and urine was collected before the 
end of the experiment. After each time point, animals were sacrificed and plasma, 
serum and kidney tissues were collected. 
Production of maFGF: 
Generation of the maFGF (aFGF28-154) has been previously described 57. Briefly, it was 
generated by amplification of appropriate DNA fragments followed by subcloning the 
products into pET vectors. The vectors were expressed in BL21 (DE3) cells (strain of E. 
coli) and purified on an M2 agarose affinity column. The powder form was then 
reconstituted in PBS and stored in -80°C until needed. 
2.2 In vitro studies 
2.2.1 Human microvascular endothelial cells (HMVEC):  
Dermal-derived human microvascular endothelial cells (HMVECs) (Lonza Walkersville, 
MD) were cultured in EBM-2 media containing 5mmol/L D-Glucose, 10% fetal bovine 
serum (FBS) (Sigma-Aldrich, Oakville, ON) and necessary supplements provided in EBM2 
single kits. Cells were grown and maintained in a humidified atmosphere containing 5% 
CO2 at 37 °C. At 80% confluence, cells were arrested in serum-free media with no growth 
factors overnight, before incubation with glucose (25mmol/L). The experiments were 
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performed after 24 or 48 hours of glucose incubation with or without maFGF 1 hour pre-
treatment, at the dose 200ug/ml or aFGF (200ug/ml) as positive control. These doses 
were chosen based on previous experiments performed in our lab with HMVEC. For 
some experiments, 500 μmol/L of N-nitro-L-arginine methyl ester hydrochloride (L-
NAME) (Sigma-Aldrich), an inhibitor of NOS, was added to the serum-free media when 
cells were arrested. Osmotic controls were also used where necessary (20mmol/L L-
glucose + 5mmol/L D-glucose). All experiments were performed with 3 to 5 replicates. 
2.2.2 Podocytes (E11 cell line) 
The E11 cell line, conditionally immortalized mouse podocytes were obtained (CLS 
Eppleheim Germany), and was handled as described 42. The growing cells were 
maintained under permissible conditions: in RPMI 1640 media (Life technologies) 
supplemented with 50 units/ml mouse recombinant- interferon Ɣ (Prospec Protein 
Specialists), 100 units/ml of penicillin/streptomycin and 100 units/ml of antimicotic in 
collagen-coated flasks at 33°C. When the cells reached 60% confluence, they were 
passage and allowed differentiating under non permissive conditions before any 
experimental manipulation: at 38°C for 14 days without interferon Ɣ in RPMI 1640 
media. Podocyte differentiation was confirmed by expression of Synaptopodin (mRNA 
expression) (Sigma-Aldrich). When confluent, cells were arrested overnight in RPMI-
1640 serum-free media containing 0.2% BSA before incubation with glucose (30mmol/L). 
The experiments were performed similar to HMVEC. The dose used for maFGF and the 
native aFGF treatment was 20ug/ml, chosen after dose-response experiments 
conducted with 5ug/ml, 10ug/ml and 20ug/ml. 
2.3 RNA extraction and real-time PCR 
RNA isolation was done using the Trizol reagent (Invitrogen Burlington, Canada) 
following the protocol established in our lab. RNA was extracted with 0.2 ml chloroform 
added to the trizol. Following centrifugation at 15000 x g for 15 mins at 4°C, the aqueous 
phase was separated from the organic phase and placed in a fresh tube. RNA was 
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recovered from the aqueous phase by isopropyl alcohol precipitation using equal 
volume of the aqueous phase. The samples were vortexed and centrifuged at 15000 x g 
for 15 mins at 4°C and the pellet was washed with 75% ethanol in diethylpyrocarbonate 
(DEPC) -treated water and dried. The total RNA was suspended in 15 ul DEPC water and 
the concentration was quantified with spectrophotometry at 260 nm (Gene Quant, 
Pharmacia Biotech, USA). Total RNA (2 ug) was used for cDNA synthesis with high 
capacity cDNA reverse transcription kit (Applied Biosystems, Foster City, USA). Real-time 
RT-PCR was performed by using the LightCycler 96 (Roche Diagnostics Canada, Laval QC) 
and SYBR Green detection (Clontech, Mountain View, USA). According to the 
manufacturer’s protocol, for a final reaction volume of 20 uL the following reagents 
were added: 10 uL SYBR Advantage qPCR Premix, 1 uL each of forward and reverse 
primers (10 mmol/L), 7 uL H2O, and 1 uL cDNA template. Primers for mouse or human β-
actin, ANG, TGFβ-1, eNOS, iNOS, FN, Col4α1, VEGF, Bcl-2 and Bak-1 are listed in table 2.1 
(Sigma-Aldrich) and HO1 were obtained (Qiagen, Germantown, MD). The mRNA levels 
were quantified by using the standard curve method. Standard curves were constructed 
by using a serially diluted standard template. The data was normalized to β-actin 
ribosomal RNA to account for differences in reverse transcription efficiencies and the 
amount of template in the reaction mixtures.  
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Table 2.1 Oligonucleotide sequences RT-PCR 
Gene Primer sequences (5’-3’): Forward 
                                                 Reverse 
β-actin (mouse/human) CCTCTATGCCAACACAGTGC 
CATCGTACTCCTGCTTGCTG 
 
VEGF (mouse/human) GGCCTCCGAAACCATGAACTTTCTGCT 
GCATGCCCTCCTGCCCGGCTCACCGC 
 
Col4α1 (mouse) ACAGGCACAAGTTAGGAAA 
ATCTCCTTTCTCTCCCAAG 
 
FN (mouse) CGGTGTTTTTTACGGGAGTTTC 
GCGCACACACTCGCACACACG 
 
TGFβ-1 (mouse) GGACTCTCCACCTGCAAGAC 
GACTGGCGAGCCTTAGTTTG 
 
iNOS (mouse) CTGGCTCGCTTTGCCACGGA 
GCTGCGACAGCAGGAAGGCA 
 
eNOS (mouse) TTGGCGGCGCAAGAGGAAGG 
TCTCGGGCAGCAGCTTTGGC 
 
ANG (mouse) CACCCCTGCTACAGTCCATT 
GTCTGTACTGACCCCCTCCA 
 
Bak1 (mouse) CATCCACCACCATGAATCCAC 
CTCCAGATGTGGGATGGCTC 
Bcl-2 (mouse) CCTGTGGATGACTGAGTACC 
GAGACAGCCAGGAGAAATCA 
Synaptopodin (mouse) TTGCTTAGGGCGCTGAGTGG 
CTCCTTCAGGTCGTTTTCGGT 
 
Col4α1 (human) CAAGAGGATTTCCAGGTCCA 
TCATTGCCTTGCACGTAGAG 
 
FN (human) GATAAATCAACAGTGGGAGC 
CCCAGATCATGGAGTCTTTA 
 
TGFβ-1 (human) CAACAATTCCTGGCGATACC 
CGAAAGCCCTGTATTCCGTCTCC 
 
eNOS (human) TCGACCCAGGATGGGCCCTG 
CGTCACGGGGTTTCTGGGGC 
 
ANG (human) GCAGATAACAACCCCGGACA 
TGCAGGCTTCTACTGCTCAC 
Bak1 (human) GGGGTGTAGATGGGGGAACT 
GGGTGAGGGGATTGCACAGTTTA 
Bcl-2 (human) TTGCTTTACGTGGCCTGTTTC 
GAAGACCCTGAAGGACAGCCAT 
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2.4 Measurement of renal parameters 
The albumin excretion was measured after 1 month and 6 months of the onset of type 1 
diabetes and normalized in relation to creatinine in order to measure renal function. 
Urinary albumin was measured using the murine microalbuminuria ELISA kit (Albuwell 
Philadelphia, PA) following the manufacturer’s protocol. Mouse urine was collected by 
placing the animals in a metabolic cage for 24 hours before the animals were 
euthanized. The collected urine was stored at -80oC for future use. Urine concentration 
for each sample was diluted relative to the standards before performing the assay. 
Duplicate samples, controls and standards were incubated with Rabbit Anti-murine 
Albumin Antibody for 30 minutes (primary incubation). After 10 wash cycles with wash 
buffer (provided by the kit), the test plate was incubated with Anti-rabbit HRP conjugate 
for 30 minutes (secondary incubation). The color development was obtained after 
washing the plate and adding the chromogenic substrate. After 5-10 minutes, the color 
stopper was added to each well to terminate the color reaction. The plate was then 
examined in a Multiskan FC Microplate Photometer (Thermo Scientific, Finland) to 
determine the absorbance at 450nm.  
The determination of creatinine was done using a Creatinine Companion kit (Albuwell 
Philadelphia, PA) to normalize albumin in relation to creatinine. The same specimens 
used for the albumin quantification were used for creatinine determination following 
the manufacturer’s protocol. The procedure uses an adaptation of the alkaline picrate 
method and requires determination of the differential absorbance in a sample before 
and after the addition of acid to correct for color generation due to interfering 
substances. Hence, the absorbance was determined on the plate reader at 500 nm in 
two different time points: 10 minutes after adding the picrate working solution and 5 
minutes after adding the acid reagent.  
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2.5 Protein extraction and ELISA  
Kidney tissues were washed with cold phosphate buffered saline (PBS) and homogenized 
in 0.4 ml RIPA lysis buffer (Upstate, Temecula CA) with a micro tissue grinder on ice. 
Homogenates were centrifuged for 5 minutes at 5000 rpm and the supernatant was 
aliquot and stored or used for the assay. The total protein concentration was measured 
using BCATM protein assay kit (Pierce, Rockford, IL, USA) according to the manufacturer’s 
instructions. The concentrations of all samples were adjusted before performing ELISA. 
We performed FN (Kamiya Biomedicals, WA, USA) and Col1 α(IV) (Cloud- Clone Corp, TX 
USA) protein measurement following the manufacturer’s protocols. 
2.6 Cellular reactive oxygen species levels 
Intracellular ROS generation was assessed using a dichlorofluorescein diacetate (DCFDA) 
Cellular ROS Detection Assay kit (Abcam Toronto, ON) according to the manufacturer’s 
instructions. Podocytes were seeded 2.5x104 cells per well on a dark 96 well microplate, 
they were allowed to adhere overnight. The next day, cells were starved overnight by 
replacing the media with serum-free media. On the following morning, cells were 
incubated with high glucose (25mmol/L) for 48 or 72 hours with or without maFGF one 
hour pre-treatment at the dose 20μ/ml or aFGF (20μg/ml) used as positive control. At 
both time points, the cells were incubated with DCFDA solution for 30 minutes at 37oC in 
the dark. Plate was read in a Gemini Fluorescence Microplate Reader with excitation 
wavelength at 485 nm and emission wavelength at 535 nm. The data generated as ratio 
of the relative fluorescence intensity of control and treated wells to the relative 
fluorescence intensity of the blank wells. Data were normalized respective to percentage 
of number of cells. 
2.7 Antioxidant enzymes activity 
Catalase and Glutathione Peroxidase activities were assessed through a Catalase assay 
kit and a Glutathione Peroxidase assay kit (Cayman Chemical Ann Arbor, MI) following 
the manufacturer’s instructions. Tissue was homogenized on ice in 5 ml of cold buffer 
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consisting in 50mM potassium phosphate, ph 7.0, containing 1mM EDTA. The 
homogenates were centrifuged for 15 minutes at 8000 rpm at 4oC. The supernatant was 
aliquot and used for the assays on the same day or stored at -80oC. Catalase activity was 
expressed as nmol of formaldehyde produced per minute in the presence of H2O2.  
Glutathione peroxidase activity was expressed as the amount of enzyme that caused the 
oxidation of 0.1 nmol of NADPH to NADP+ per minute. Both enzymes activity were 
reported respective to ug of proteins. 
2.8 NO Assay 
Total Nitric Oxide production was measured in kidney tissue homogenates and cell 
lysates using a fluorometric nitric oxide assay (Abcam, Toronto Ontario). The total 
concentration of nitrite and nitrate was used as a quantitative measure of NO 
production. The enzyme cofactor working solution for Nitrate Reductase was added to 
the wells followed by the addition of Nitrate Reductase. In this step nitrate is converted 
to nitrite. The plate was incubated at room temperature for 2 hours. Afterwards, 
enhancer was added and incubated for 30 minutes to quench interfering compounds. 
The fluorescent probe DAN (2, 3-diaminonaphthalene) that reacts with nitrite, was 
added and incubated for 10 minutes followed by the addition of NaOH for 10 minutes to 
increase the fluorescent field. The plate was read in a Gemini Fluorescence Microplate 
Reader with excitation wavelength at 360 nm and emission wavelength at 450 nm. 
2.9 TUNEL Assay 
Apoptotic assays were performed by Terminal deoxynucleotidyl transferase-mediated 
dUTP nick end labeling (TUNEL) reaction using In Situ Apoptosis Detection Kit (Takara Bio 
Inc). Podocytes were cultured on eight-chamber tissue culture slides and incubated for 
48 hours with the presence of glucose (25mmol/L) and maFGF (20μg/ml), aFGF 
(20μg/ml) was used as positive control. The cells were counterstained with DAPI for 
nuclear staining. 
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For tissues embedded in paraffin, deparaffinization and rehydration (using xylene and 
ethanol dilutions) was performed. The sections were treated with proteinase K (20 
mg/L) for 15 min and then incubated with the TUNEL reaction mixture containing 
terminal deoxynucleotidyl transferase (TdT) and digoxigenin-11-dUTP for 1 h. The TdT 
reaction was carried out in a humidified chamber at 37°C. For the negative control, TdT 
was omitted from the reaction mixture. Apoptotic cell death was quantitatively analyzed 
by counting the TUNEL-positive cells selected randomly from 10 fields. Microscopic 
observation was performed by an examiner unaware of the identity of the sample, using 
a Zeiss LSM 410 inverted laser scan microscope equipped with fluorescein, rhodamine, 
and DAPI filters (Carl Zeiss) 
2.10 Western Blotting 
Kidney tissues or cell extracts were sonicated and lysed in 0.4 ml or 0.1 ml RIPA (Upstate, 
Temecula CA) lysis buffer respectively. The tissue and cell extracts were centrifuged at 
3000 rpm at 4°C for 30 minutes to remove cell debris. The total protein concentration 
was measured using BCATM protein assay kit (Pierce, Rockford, IL, USA) using BSA as 
protein standard. Proteins were electrophoresed through a 10% SDS-PAGE gel before 
transferring to a PVDF membrane. After blocking for 30 minutes at 4°C in blocking buffer 
(3% BSA in PBS with 0.1% Tween 20), the membrane was incubated overnight with 
mouse anti-eNOS (1:1000) or mouse anti-peNOS (1:1000) (Santa Cruz Biotechnology, 
Inc). The membrane was washed and incubated for 30 minutes at room temperature 
with a goat anti-mouse antibody conjugated with HRP. After further washing, the 
membrane was detected with ECL kit (Amersham Pharmacia Biotech, Arlington, IL, USA). 
β-actin was used as an internal controls and detected by rabbit anti- β-actin antibody 
conjugated with HRP. Western blotting images were captured by Kodak 4000 mm and 
density of the bands was quantitated by using ImageJ 
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2.11 Cell Viability Assay 
To determine the effects of maFGF treatment in the proliferation of HMVEC, the WST-1 
Cell Viability Assay (Roche) was used. Cells were seeded (aprox. 5 x 104/well) onto a 96-
well plate and were allowed to attach overnight. Starting on the following day, cells 
were starved overnight by replacing the media with serum-free media. The next 
morning, maFGF (200ug/ml) was added to the wells for 6, 20, 24 or 48 hours. After each 
time point, 10μL of WST-1 reagent was added to each well and the plates were 
incubated for 1 hour at 37°C to produce a colour reaction. Absorbance was measured in 
a Multiskan FC Microplate Photometer (Thermo Scientific, Finland) at 450nm with a 
reference wavelength of 690nm.  
2.12 Immunofluorescence 
HMVECs cells were plated on eight-chamber tissue culture slides and incubated for 48 
hours with the presence of glucose (5 mmol/L, 25mmol/L) and maFGF (200μg/ml) or 
aFGF (200μg/ml), then these cells were fixed with ethanol for staining with 8-OHdG 
antibody (Santa Cruz Biotehnology, Dallas). Goat IgG labeled with FITC (Vector 
Laboratories, Burlingame, CA) was used for detection of the fluorescence. Slides were 
mounted in Vectashield fluorescence mounting medium with 4, 6-diamidino-2-
phenylindole (DAPI; Vector Laboratories, Burlingame) for nuclear staining. Microscopic 
observation was performed by an examiner unaware of the identity of the sample, using 
a Zeiss LSM 410 inverted laser scan microscope equipped with fluorescein and DAPI 
filters (Carl Zeiss)  
2.13 Immunohistochemistry 
Formalin-fixed tissues embedded in paraffin were sectioned at 5 μm thickness on 
positively charged slides. The kidney tissues were analyzed for 8-hydroxy-2- 
deoxyguanosine (8-OHdG) (Chemicon International Inc. CA, USA). The chromogen 3,3- 
diamino benzine (Sigma-Aldrich) was used for detection. Non-immune horse serum was 
used as a negative control. 8-OHdG immunoreactivity was assessed by the presence of 
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positively stained nuclei in the glomeruli with a dark brown color. The dark brown-
stained nuclei were counted as a measurement of 8-OHdG immunoreactivity and the 
results were expressed as percentage of positive nuclei respective to the total number 
of nuclei in each glomerulus. The measurement was done in 15 glomeruli for each 
sample (n=2).  
2.14 Histological Analysis 
Formalin-fixed tissues embedded in paraffin were sectioned at 5 μm thickness on 
positively charged slides. The sections were stained with hematoxylin and eosin and 
periodic acid-schiff stain (PAS). The PAS stain is used to detect extracellular matrix proteins 
deposition and it gives a purple magenta color as indication of the presence of glycogen, 
proteoglycans, glycoproteins and glycolipids.  
2.15 Statistical analysis 
Data is presented as mean ± standard error. Statistical significance of differences 
between groups was tested with Student’s T-test for two groups or one-way ANOVA 
with multiple comparisons (post hoc analysis) for multiple groups. A p-value of 0.05 or 
less was considered to be statistically significant. All calculations were performed with 
GraphPad Prism version 5.03 software. 
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Chapter 3: Results 
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3.1 MaFGF treatment did not affect body weight and blood glucose but decreased 
renal hypertrophy following long term diabetes. 
After inducing type 1 diabetes in specific groups of mice, diabetic and age-matched non 
diabetic mice were divided into groups with and without treatment with maFGF 
(10μg/Kg daily) for 1 month and 6 months. The body and kidney weights and blood 
glucose of each group of mice were evaluated after each time point. The body weights 
were not significant different among the groups at 1 month after the treatment. 
However the diabetic animals showed a significantly decreased in body weight at 6 
months compared to non-diabetic groups. At the same time, the blood glucose was 
significantly increased in diabetic animals with or without treatment with maFGF both at 
1 month and 6 months. Similarly, the ratio kidney weight- tibia length was significantly 
increased in the diabetic groups at both time points which is probably result of the 
hypertrophy and increased filtration area of the glomeruli as result of diabetes. 
MaFGF treatment didn’t show any effects in the body weight and blood glucose 
compared to the untreated diabetic group after 1 month or 6 months (Fig 3.1-A). 
However, the kidney weight- tibia length ratio was significantly reduced in the diabetic 
group after treatment for 6 months (Fig 3.1-B) which indicates prevention of renal 
hypertrophy.  
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Figure 3.1 Effects of maFGF on body weight, blood glucose levels and kidney 
weight/tibia length ratio in non-diabetic and diabetic mice after (A) 1 month and (B) 6 
months of treatment with maFGF. MaFGF had no effect on body weight or blood glucose 
levels. However it prevented renal hypertrophy after 6 months of follow up. C: control, 
maFGF: modified aFGF, DM: diabetes mellitus, DM+maFGF: diabetic treated with 
maFGF.*p<0.05 vs control, # p<0.05 vs. maFGF, & p<0.05 vs. DM group. 
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3.2 MaFGF treatment prevented functional damage 
Microalbuminuria is an established marker for the renal dysfunction in DN. Following 
onset of type 1 diabetes the glomerular filtration rate increases due to increased renal 
blood flow, glomerular capillary hypertension and increased filtration surface. 
Interestingly, increased excretion of albumin happens and persists along with the 
declining of GFR which is the result of progressive reduction of the filtration surface 
possibly due to mesangial expansion 9. We measured the albumin-to-creatinine ratio (µg 
albumin/mg creatinine) which is an alternative to 24 urine collection in the detection of 
microalbuminuria to assess nephropathic change. The results showed that the albumin-
to-creatinine ratio significantly increased in the diabetic groups. MaFGF treatment 
prevented renal functional alterations in diabetes at 1 and 6 months as shown in figure 
3.2. 
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Figure 3.2 Effects of maFGF on albuminuria in Diabetic Nephropathy. Urinary albumin-
to-creatinine ratio with or without maFGF treatment at 1 or 6 months in diabetic and 
non-diabetic mice. maFGF prevented diabetes induced albuminuria at both time points. 
maFGF: modified aFGF, DM: diabetes mellitus, DM+maFGF: diabetic treated with 
maFGF.*p<0.05 vs control, # p<0.05 vs. maFGF, & p<0.05 vs. DM group. 
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3.3 MaFGF treatment prevented vasoactive factors alterations in DN. 
Current evidence suggests the elevation of several vasoactive factors in early DN such as 
angiotensinogen (AGT), Nitric Oxide and vascular endothelial growth factor (VEGF). 
Various of these factors are also associated with elevation of systemic and 
intraglomerular pressure and increased permeability 8, 9, 11. With progression of DN, the 
levels of some of these factors (NO, VEGF) fall possibly due to continue endothelial 
dysfunction leading to the arrest of endothelial growth and apoptosis. Results show that 
maFGF treatment prevented diabetes induced alteration of the vasoactive factors 
transcripts AGT, eNOS, iNOS and VEGF compared to diabetic groups (Figure 3.3). The 
changes were pronounced after 6 months and maFGF treatment prevented such 
changes.  
The control group for the maFGF treatment didn’t show significant difference respective 
to the control group (non diabetic mice) in the analysis of the transcripts or subsequent 
analysis performed; therefore it was omitted from the figures. 
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Figure 3.3 Effects of maFGF treatment on vasoactive factor regulation in Diabetic 
Nephropathy. Quantitative RT-PCR analysis of diabetes induced mRNA expression in 
mouse kidneys after 1 month and 6 months with maFGF treatment. The treatment 
prevented increased production of (A) Angiotensinogen (AGT) and significantly 
prevented down-regulation of (B) endothelial Nitric Oxide Synthase (eNOS), (C) inducible 
Nitric Oxide Synthase (iNOS) and (D) Vascular Endothelial Growth Factor (VEGF) at the 
later time point (6 months). DM: diabetes mellitus, DM+maFGF: diabetic treated with 
maFGF.*p<0.05 vs control, # p<0.05 vs. DM group. 
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3.4 MaFGF treatment decreased diabetes-induced oxidative stress and DNA damage in 
the kidney 
Development of DN is related to the induction of renal oxidative stress. We examined 
the effects of diabetes-induced oxidative stress through various methods in kidney 
tissue of type 1 diabetic mice. Diabetic animals showed increased HO1 transcript levels, 
a marker of oxidative stress, at 1 month and 6 months after the onset of diabetes (Figure 
3.4-A). Treatment with maFGF reduced the upregulation of this enzyme at both time 
points. We further assessed the activity of enzymes that are activated by oxidative stress 
such as Catalase (Figure 3.4-B) and Glutathione peroxidase (Figure 3.4-C). Such activity 
was increased in diabetes and reduced with the maFGF treatment after 1 month and 6 
months with significant difference in the case of Catalase activity. In addition, DNA 
damage of kidney tissues showed increased immunohistochemical staining for 8-OHdG 
(Figure 3.4-D) in the nuclei of glomeruli cells of diabetic animals and the treatment with 
maFGF reduced the number of positive cells. 
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Figure 3.4 Effects of maFGF treatment on diabetes induced oxidative stress. RT-PCR 
analysis of diabetes induced mRNA expression for the enzyme (A) Heme Oxygenase 1 
(HO1), a marker for oxidative stress, in mouse kidneys after 1 month or 6 months with 
maFGF treatment. (B) Catalase (Cat) activity (expressed as nmol of formaldehyde 
produced/min in the presence of H2O2 respective to μg of protein) and (C) Glutathione 
peroxidase (GPx) activity (expressed as the amount of enzyme that caused the oxidation 
of 0.1 nmol of NADPH to NADP+/min respected to μg of proteins) indicating that 
diabetes-induced Cat and GPx activities were reduced by maFGF treatment at both time 
points. DM: diabetes mellitus, DM+maFGF: diabetic treated with maFGF.*p<0.05 vs 
control, # p<0.05 vs. DM group. 
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Figure 3.4- (D) Effect of maFGF treatment on diabetes induced oxidative DNA damage. 8-
OHdG shows diabetes-induced increased positivity in the glomeruli cells and the 
preventative effects of maFGF treatment versus diabetic. 8-OHdG: 8-hydroxy-2-
deoxyguanosine. Magnifications 60X, arrows indicate positive nuclei. n=2x15 glomeruli. 
DM: diabetes mellitus, DM+maFGF: diabetic treated with maFGF.*p<0.05 vs control, # 
p<0.05 vs. DM group. 
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3.5 MaFGF partially prevented fibrotic response in DN 
Fibrosis is one of the hallmarks of DN. The increased deposition of extracellular matrix 
proteins (ECM) leads to diffuse thickening of the glomerular and tubular basement 
membranes and mesangial matrix expansion. We investigated the effects of maFGF 
treatment on the diabetes induced alteration of the fibrogenic cytokine TGF-β1 and 
extracellular matrix proteins FN and Col 1α (IV).  
The results showed that the induced fibrogenic cytokine TGF-β1 was not prevented by 
maFGF treatment, as shown in the mRNA expression. However, the maFGF treatment 
showed some preventive effects on alterations of the ECM protein FN and Col 1α (IV) 
mRNA (Figure 3.5) and protein expression (Figure 3.6), especially when the maFGF was 
administered for longer period. Histological analysis of the extracellular matrix in the 
kidney through acid-Schiff stain (PAS) was performed to conclude whether these 
molecular alterations produced structural changes in the organ (Figure 3.7). These stains 
confirmed deposition of extracellular matrix proteins in diabetes suggestive of mesangial 
expansion, as it was previously indicated by upregulated transcripts and protein 
expression of Col 1α (IV). The maFGF treatment failed to prevent the fibrogenic factor 
TGF-β1, although partially prevented diabetes-induced upregulation of extracellular 
matrix proteins.    
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Figure 3.5 Effects of maFGF treatment on diabetes induced alterations of fibrosis-related 
genes. Quantitative RT-PCR analysis of diabetes induced mRNA expression for (A) the 
fibrogenic cytokine TGFβ1 and extracellular matrix proteins (B) FN and (C) Col 1 α (IV) in 
mouse kidneys after 1 month or 6 months with maFGF treatment. maFGF treatment 
failed to prevent the fibrogenic factor TGF-β1, although partially prevented diabetes-
induced upregulation of extracellular matrix proteins after 6 months. Con: control, DM: 
diabetes mellitus, DM+maFGF: diabetic treated with maFGF.*p<0.05 vs control, # p<0.05 
vs. DM group. 
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Figure 3.6 Effects of maFGF treatment on ECM proteins expression. (A) fibronectin and 
(B) collagen 1 α (IV) protein expression in non- diabetic and diabetic mouse kidneys after 
1 month or 6 months with maFGF treatment. Con: control, DM: diabetes mellitus, 
DM+maFGF: diabetic treated with maFGF.*p<0.05 vs control, # p<0.05 vs. DM group. 
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Figure 3.7 Histologic analysis using PAS stain confirmed the molecular results indicating 
that the maFGF treatment partially prevented diabetes-induced mesangial expansion 
versus diabetes. Magnifications 60X, arrows indicate increased extracellular matrix 
proteins deposition represented by areas stained purple magenta. 6 months samples 
DM-Diabetes Mellitus, DM+maFGF-Diabetic treated with maFGF. 
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3.6 MaFGF treatment prevented high-glucose induced oxidative stress and damage  
Our in vivo study showed that maFGF treatment significantly prevented functional 
damage in the kidney at 1 month and 6 months and partially prevented structural 
changes. We further assessed the effects of maFGF on oxidative stress as a key 
mechanism causing DN; the results showed that maFGF treatment prevented diabetes 
induced upregulation of the oxidative stress marker Heme Oxygenase (HO1).  Moreover, 
maFGF prevented diabetes-induced increased activity of the antioxidant enzymes 
catalase and glutathione peroxidase and oxidative DNA damage in the glomerulus of 
diabetic mice.   
We further investigated how the maFGF treatment affects two of the various cellular 
elements of the kidney that are targets of high glucose injury. We intended to explore 
the effects of maFGF treatment in high glucose induced alteration in microvascular 
endothelial cells and mouse glomerular epithelial cells (podocytes). Microvascular 
endothelial cells play an important role in the pathophysiology of DN and have been 
used to reproduce diabetic vascular complications in our laboratory. Podocytes are 
specialized visceral epithelial cells acting as the final barrier to molecular flowing during 
urine filtration. Furthermore, podocytes are closely related and in proximity with 
endothelial cells in the glomeruli comprising the glomerular filtration barrier in a way 
that the action of one type of cell may influence the function of the other. 
Hence, we examined various parameters, consistent with those considered in vivo, in 
dermal- human derived microvascular endothelial cells and podocytes. In previous 
studies in our lab, it was shown that the treatment of HMVEC with maFGF prevented 
high glucose-induced increase of cellular ROS levels 61. We confirmed these results 
investigating oxidative DNA damage in HMVEC using the sensitive immunofluorescent 
staining of 8-OHdG. The positive staining increased in HMVECs after 48-hour of high 
glucose treatment (Figure 3.8). The increased 8-OHdG stain in the nucleus induced by 
exposure to high glucose was significantly attenuated by treatment with both maFGF 
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(200μg/ml) and the native aFGF (200μg/ml) used as positive control. The 8-OHdG 
staining shown in green was co-localized with the blue of nuclear dye DAPI.  
Our experiments with podocytes showed similar results for cellular ROS levels under the 
same experimental conditions. After 1 hour pre-treatment of differentiated podocytes 
with maFGF (20μg/ml) or aFGF (20 μg/ml)  followed by 48 and 72 hours treatment with 
high glucose, the upregulation of cellular ROS was significantly prevented (Figure 3.9). 
Additionally, we detected mRNA expression of the enzyme HO1 in HMVEC and 
podocytes. The results showed high glucose-induced significant upregulation of this 
transcript which is prevented by the treatment with both maFGF and the native aFGF 
after 24 and 48 hours of treatment with high glucose (Figure 3.10-A, 3.10-B).  
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Figure 3.8 Effects of maFGF treatment on high glucose induced DNA oxidative damage in 
HMVEC. Cells were incubated with high glucose (25 mmol/L) and maFGF (200μg/ml) or 
aFGF (200μg/ml) for 48 hours. Immunocytochemistry analysis of 8-OHdG and DAPI (for 
nuclear morphology) was performed using fluorescence microscopy. 8-OHdG is shown in 
green (left column) and DAPI staining in blue (middle column). Images were merged 
(right column). The increased 8-OHdG stain in the nucleus induced by exposure to high 
glucose was significantly attenuated by treatment with both maFGF and the native aFGF. 
Magnifications 60X. 8-OHdG: 8-hydroxy-2-deoxyguanosine, DAPI: 4, 6-diamidino-2-
phenylindole. NG: Normal Glucose, HG: High Glucose 
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Figure 3.9 Effects of maFGF (20μg/ml) and the native aFGF (20μg/ml) treatment on high 
glucose- induced oxidative stress in podocytes. Both native and maFGF prevented high 
glucose induced increased production of cellular ROS levels.  Data presented respective 
to percentage of number of cells. n=6. NG: Normal Glucose. *p<0.05 vs. control (NG), # 
p<0.05 vs. high glucose (HG)  
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Figure 3.10 Effects of maFGF or native aFGF on high glucose induced oxidative stress in 
(A) HMVEC and (B) podocytes- RT-PCR analysis of mRNA expression for the enzyme 
Heme Oxigenase 1 (HO1). Pre-treatment for 1 hour with maFGF or native aFGF followed 
by 24 and 48 hours treatment with high glucose. Both native aFGF and maFGF prevented 
high glucose induced up-regulation of HO1 mRNA expression in both cell types at both 
time points. All in vitro data was obtained from at least 3 independent experiments. NG: 
Normal Glucose. *p<0.05 vs. control (NG), # p<0.05 vs. high glucose (HG) 
 
50 
 
 
3.7 MaFGF treatment prevented high glucose induced vasoactive factors alteration   
Results in our in vivo study showed that maFGF treatment prevented diabetes induced 
upregulation of AGT and downregulation of eNOS in the context of progressive diabetic 
nephropathy. Therefore, we investigated the effects of maFGF which is known by its 
vasodilator properties, in the expression of these factors in endothelial cells and 
podocytes.  
We found that podocytes express eNOS and this expression is affected by high glucose 
after exposure for 48 hours similar to the high glucose induced effects in endothelial 
cells eNOS expression (Figure 3.11-A). The eNOS mRNA expression is suppressed under 
high glucose condition and the maFGF treatment significantly prevented high glucose 
induced down-regulation of this transcript. We also tested the effects of maFGF in high 
glucose induced upregulation of AGT mRNA expression in HMVEC and podocytes at 48 
hours. maFGF treatment significantly prevented this alteration in both cell types (Figure 
3.11-B). 
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Figure 3.11 Effects of maFGF or native aFGF treatment on high glucose induced 
alteration of vasoactive factors- Quantitative RT-PCR analysis of high glucose-induced 
mRNA expression of (A) endothelial Nitric Oxide Synthase (eNOS) and (B) 
Angiotensinogen (AGT) in HMVEC and podocytes after 1 hour pre-treatment with maFGF 
or native aFGF followed by 48 hours treatment with high glucose. Both native aFGF and 
maFGF prevented high glucose induced alteration of AGT and eNOS mRNA expression in 
both cell types. NG: Normal Glucose. *p<0.05 vs. control (NG), # p<0.05 vs. high glucose 
(HG) 
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3.8 MaFGF partially prevented high glucose induced fibrotic response 
MaFGF partially prevented fibrosis in our in vivo study. Hence, we examined the 
expression of the fibrosis-related genes TGFβ1, FN and Col 1α (IV), under high glucose 
condition in HMVEC and podocytes. The results showed that mRNA expression of these 
transcripts was significantly upregulated after 48 hours (Figure 3.12). The maFGF 
significantly prevented the high glucose induced upregulation of the extracellular matrix 
protein transcripts FN and Col 1α (IV) in podocytes but failed to prevent the 
aforementioned up-regulation in HMVEC (Figure 3.12-B, 3.12-C). Additionally, it failed to 
prevent the high glucose induced up-regulation of the fibrogenic cytokine TGFβ1 in both 
cell types (Figure 3.12-A). 
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Figure 3.12 Effects of maFGF or native aFGF treatment on high glucose induced up-
regulation of fibrosis-related genes - Quantitative RT-PCR analysis of high glucose-
induced mRNA expression of (A) Transforming Growth Factor β1 (TGFβ1), (B) Fibronectin 
(FN)  and (C) Collagen 1α (IV) (Col 1α(IV)) in HMVEC and podocytes after 1 hour pre- 
treatment with maFGF or native aFGF followed by 48 hours treatment with high glucose. 
maFGF or native aFGF failed to prevent glucose-induced upregulation of the fibrogenic 
factor TGFβ1 expression in both cells types and FN and  Col 1α (IV) in HMVEC; whereas it 
prevented upregulation of the later in the podocytes. NG: Normal Glucose. *p<0.05 vs 
control (NG), # p<0.05 vs. high glucose (HG). 
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3.9 MaFGF treatment activated eNOS enzyme and enhanced production of Nitric Oxide 
in the kidney 
Evidence reveals that FGFs stimulate the expression of eNOS and the production of NO 
50-54, which is known to play a key role in vascular homeostasis.  Our study shows that 
maFGF treatment stimulates the expression of eNOS mRNA in the kidney in the context 
of diabetes induced suppression of eNOS expression. Moreover, we found similar results 
in high glucose induced alterations in HMVEC and podocytes after 48 hours.  
On the other hand, uncoupling of nitric oxide synthase is one of the known pathways 
that generate ROS in the kidney and has been identified as potentially major contributor 
to the pathogenesis of diabetic kidney disease 15, 20-23. eNOS uncoupling leads to 
production of superoxide anion rather than NO. Our in vitro study and current studies in 
our lab showed that maFGF treatment prevented high glucose-induced oxidative stress 
in glomerular epithelial cells and microvascular endothelial cells. maFGF also showed 
prevention of oxidative DNA damage in endothelial cells. Simultaneously, our in vivo 
study illustrated that maFGF treatment significantly prevented functional damage in the 
kidney and had protective effects against diabetes induced oxidative stress.   
To further explore the possible mechanism by which maFGF treatment exerts the 
aforementioned effects, we intended to check the levels of activated eNOS protein 
expression and NO production in the kidney as an indication of eNOS activity in a 
coupled state. The results showed that the upregulation of eNOS mRNA in diabetic 
animals treated with the maFGF was accompanied by increase levels of the eNOS 
protein (Figure 3.13-A) and the 1177-serine phosphorylation status of eNOS (Figure 
3.13-B).  The levels of NO production, which indicate the function of eNOS enzyme in a 
coupled state, were slightly downregulated in diabetic compared to the basal levels of 
control. The treatment of diabetic animals with maFGF increased significantly NO 
production (Figure 3.14). Furthermore, similar results were obtained in our in vitro study 
which showed that under high glucose conditions for 48 hours the production of NO is 
reduced significantly in both cell types: microvascular endothelial cells and podocytes 
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(Figure 3.15). The treatment with maFGF restored NO production with significant 
difference in the case of HMVEC.  
We also examined the effects of maFGF treatment in the activation of the enzyme 
producing NO by incubating the cells with L-NAME, a non specific NOS inhibitor. Under 
normal conditions, the incubation of the cells with L-NAME decreased significantly the 
production of NO and the treatment with maFGF restored NO production comparable to 
the control group (figure 3.16) 
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Figure 3.13 Western Blot analysis for total protein expression of (A) endothelial Nitric 
Oxide Synthase (eNOS) or (B) serine (1177) phosphorylated eNOS in kidney tissues in 
diabetic animals after 6 months of treatment with maFGF. With maFGF treatment the 
levels of eNOS protein and the serine phosphorylation status of eNOS, which indicates 
activation, increased in the context of diabetes. maFGF: modified aFGF, DM: diabetes 
mellitus, DM+maFGF: diabetic treated with maFGF.*p<0.05 vs control, # p<0.05 vs. DM. 
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Figure 3.14 Effects of maFGF treatment in total Nitric Oxide (NO) production in kidney 
tissues of diabetic animals after maFGF treatment for 6 months. The production of NO 
was increased by the treatment with maFGF. maFGF: modified aFGF, DM: diabetes 
mellitus, DM+maFGF: diabetic treated with maFGF. #p<0.05 vs. DM group 
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Figure 3.15 Effects of maFGF treatment in total Nitric Oxide (NO) production in high 
glucose induced alterations in (A) HMVEC and (B) podocytes. Under high glucose 
conditions for 48 hours the production of NO is significantly reduced in both cell types 
and treatment with maFGF restored such reduction. NG: Normal Glucose. *p<0.05 vs. 
control (NG), # p<0.05 vs. high glucose (HG) 
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Figure 3.16 Effects of maFGF treatment in total Nitric Oxide (NO) production after 
incubation with L-NAME (500 μmol/L) (an inhibitor of Nitirc Oxide Synthase enzymes) for 
48 hours in (A) HMVEC and (B) podocytes. Incubation of cells with L-NAME significantly 
decreased the production of NO and the treatment with maFGF restored NO production 
comparable to the control group. NG: Normal Glucose, L-NAME: N-nitro-L-arginine 
methyl ester hydrochloride.*p<0.05 vs. control (NG), # p<0.05 vs. high glucose (HG). 
 
 
 
 
 
 
 
61 
 
 
3.10 MaFGF treatment inhibits apoptosis in diabetes  
Albuminuria is often the first evidence of kidney injury in diabetes. Results from our in 
vivo study illustrated that maFGF prevented functional damage in kidneys of diabetic 
mice by preventing increased albumin to creatinine ratio. Urinary albumin content is 
considered to reflect the underlying pathology of endothelial dysfunction and damage to 
glomerular podocytes 65. Indeed, the progression of DN correlates with podocyte loss 
due to apoptosis, and hyperglycemia leads to decreased endothelial cell survival. In view 
of this evidence and the prevention shown by maFGF treatment against oxidative stress 
and oxidative DNA damage, we tested the possible effect that maFGF could trigger in 
the apoptosis of HMVEC and podocytes under high glucose conditions.  We evaluated 
apoptosis through the mRNA expression of antiapopototic (B-cl2) - proapototic (Bak-1) 
ratio. Results showed that, in both cell types, the ratio Bcl-2/Bak-1 was significantly 
reduced under high glucose conditions (Figure 3.17). The treatment with maFGF 
restored this reduction in both cases with significant difference in HMVEC (Figure 17-A). 
Additionally, TUNEL assay after 6 months showed increased TUNEL positive cells (Figure 
3.18). maFGF treatment of diabetic mice prevented such positivity. 
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Figure 3.17 Effects of maFGF treatment on apoptosis. Quantitative RT-PCR analysis of 
high glucose-induced mRNA expression of Bcl-2 (antiapoptotic)- Bak-1 (pro-apoptotic) 
ratio in (A) HMVEC and (B) podocytes after 1 hour pre- treatment with maFGF or native 
aFGF followed by 48 hours treatment with high glucose. maFGF or native aFGF 
treatment increased the ratio Bcl-2/Bak-1 transcripts under high glucose conditions. NG: 
Normal Glucose. *p<0.05 vs. control (NG), # p<0.05 vs. high glucose (HG) 
 
 
 
 
 
 
 
 
 
 
 
63 
 
 
 
 
Figure 3.18 Effect of maFGF treatment in apoptosis in vivo. TUNEL assay 
immunofluorescence in kidney tissue of non-diabletic and diabetic animals after 
treatment with maFGF for 6 months. Diabetes-induced glomerular TUNEL positivity 
(indicated with arrows) was prevented by maFGF treatment. Magnifications 40X. C: 
Control, DM: Diabetes Mellitus, DM+maFGF: diabetic treated with maFGF. 
 
 
 
 
 
 
 
 
 
 
64 
 
 
 
 
 
 
 
 
 
 
Chapter 4: Conclusions 
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4.1 Discussion 
4.1.1 maFGF as a potential approach to prevent Diabetic Nephropathy 
Diabetes and its complications are devastating medical problems. Worldwide, there is 
increased incidence and prevalence of diabetic complications. DN, one of the very 
debilitating diabetic problems, commonly progresses to end stage renal disease unless 
preventive strategies are implemented in the initial stages. It has been proposed that 
oxidative stress is a key component in the development of DN leading to pathological 
changes such as endothelial dysfunction, decreased cell survival, podocyte loss and 
eventually, glomerulosclerosis and interstitial fibrosis.  In view of this fact, the search of 
new insights into the understanding of the pathophysiology of this disease and new 
therapeutic concepts with reasonably designed antioxidant approaches is a necessity. 
The protective effects of FGFs in the context of oxidative stress have been well 
documented 45-49, 58-60.  On the other hand, under pathological conditions such as DN, 
there are reports of upregulation of bFGF 32. Concomitantly, some studies have shown 
that aFGF is upregulated by oxidative stress 66. This evidence suggests that the increase 
in expression of FGFs could be an adaptive response to protect the tissues against 
oxidative stress.  Alternatively, FGFs are also implicated in pathological conditions such 
as tumorigenesis and metastasis due to their potent mitogenic activity. However, the 
use of modified forms of FGFs, including maFGF in order to annul its mitogenic function 
have been tested in several studies that demonstrate they can keep its vasodilator and 
survival actions 38, 55, 57-61.    
In the context of diabetes, studies done by us and others have revealed protective roles 
of bFGF and aFGF in the hearts of type 1 diabetic mouse models 61, 67. Moreover, recent 
work has demonstrated that both aFGF and a non mitogenic form of aFGF (maFGF) that 
lacked oncogenicity, showed similar protective effects on diabetic cardiomyopathy 61. 
This protection is thought to be mediated by suppression of oxidative stress and 
damage. With this perspective, we examined if maFGF may induce protection in DN. 
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Thus, we investigated such effects using a variety of approaches ranging from 
biochemical to structural and functional studies. We employed a type 1 diabetes mouse 
model and cell lines exposed to high glucose for the identification of possible 
mechanisms. 
4.1.2 Prevention of DN by maFGF is probably mediated by attenuation of oxidative 
stress. 
In the present study, the DN was established in low-dose STZ-induced type 1 diabetic 
mouse models, which were examined at 1 month and 6 months. The diabetic mice 
showed significant renal dysfunction as evidence by increased albuminuria. We showed 
for the first time that maFGF treatment significantly prevented renal dysfunction at both 
time points.  
DN is considered to be in large part a glomerular disease that is identified by the 
development of functional and morphologic abnormalities secondary to hyperglycemia 
67. It is postulated that oxidative stress plays a key role in the sequence of events 
accompanying development of glomerular and renal injury 15, 16. Hyperglycemia triggers 
increased production of ROS in renal cells that surpasses the local antioxidant capacity, 
which in normal conditions would keep the oxidative balance. This imbalance between 
ROS and antioxidants results in harmful effects in renal cells, causing changes in cellular 
function and eventually cell death.  
Here, we demonstrated diabetes- induced upregulation of HO1 mRNA, a marker of 
oxidative stress, and increased activity of the antioxidant enzymes Catalase and 
Glutathione peroxidase. All such abnormalities were prevented by maFGF treatment.  
Our results are consistent with studies that have shown that Glutathione peroxidase and 
Catalase mRNA expression and activities are increased under conditions of high glucose 
and in the renal cortex of diabetic rats 68, 69, corresponding with increased oxidative 
stress. However, decreases in expression and sometimes in the activities of antioxidants 
enzymes such as superoxide dismutase (SOD) have been reported in DN 15, 70. Reduced 
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antioxidant capacity is also one of the causes that lead to increased oxidative stress in 
diabetic conditions. Although we did not assess the activity of SOD enzymes in this study 
maFGF was shown to exert increased activity of superoxide dismutase (SOD) in a model 
of ischemia- reperfusion injury in which maFGF showed protective effects in the brain 
60). However maFGF did seem to have a direct effect in the activity of the antioxidant 
enzymes assessed in this study. Our findings suggest that some of the observed effects 
of maFGF are possibly mediated through a mechanism related to decreasing oxidative 
stress. 
Since hyperglycemia is thought to be the main cause that produces alterations in 
diabetic complications, we performed mechanistic studies exposing HMVEC and 
podocytes to high glucose for mimicking diabetes like conditions in vitro. Podocytes and 
endothelial cells are closely related in the glomerular filtration barrier. They affect the 
behaviour of the glomerular filtration membrane. 
Oxidative stress may cause podocyte damage and loss. This represents an early change 
in DN related to microalbuminuria and progressive proteinuria; leading to 
glomerulosclerosis. Concurrently, endothelial dysfunction occurs and also leads to 
glomerulosclerosis 71. For these studies, we added native or modified aFGF into the 
medium of podocytes or HMVEC cell culture to investigate whether aFGF can induce 
anti-oxidative effects in these cells under high glucose conditions. The level of ROS and 
HO1 were examined in podocytes. We found that both ROS and HO1 mRNA levels were 
increased under high glucose conditions and were significantly attenuated by either 
native aFGF or maFGF. This implies that anti-oxidative function of aFGF might be the 
mechanism to prevent podocyte injury and kidney dysfunction in the context of 
diabetes. Similar results were obtained when we assessed the possible protection by 
maFGF on endothelial cells. maFGF prevented high glucose-induced upregulation of HO1 
expression. This is in keeping with other studies done in our lab demonstrating 
attenuation of high glucose induced ROS levels in this cell type 61. 
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Increased levels of ROS in the cells initiate an array of damaging reactions which can 
damage lipids, proteins, and DNA 15. Therefore, in the present study we also tried to 
determine whether maFGF treatment could protect oxidative DNA damage in kidney 
tissues of diabetic animals and endothelial cells exposed to high glucose. We 
demonstrated increased positive 8-OHdG staining, a marker of oxidative DNA damage, in 
the nuclei of glomeruli cells after 6 months of onset diabetes. The treatment with 
maFGF reduced the number of positive cells, suggesting that prevention from oxidative 
stress prevents subsequent DNA damage. Similarly, after incubation of HMVEC in high 
glucose, increase 8-OHdG staining was evident compared to those under normal 
conditions. Nonetheless, maFGF or aFGF prevented such damage indicating that maFGF 
protects high glucose-induced oxidative DNA damage in HMVEC. It is to be noted that 
the high glucose exposed cells had also higher 8-OHdG stain in the cytoplasm. Exact 
reason is not clear. However, possibility that this may represent damaged mitochondrial 
DNA cannot be excluded.  
4.1.3 Protection of DN by maFGF may be in part through mechanisms involving 
prevention of AGT and eNOS alteration which prevent cellular dysfunction.  
Under high glucose ambience, a cross talk between metabolic and hemodynamic factors 
operates in the kidney. Like the ROS that amplify hyperglycemia injury, increased 
glomerular capillary pressure also contributes to the acceleration of diabetes- related 
alterations 8, 9, 11-13. High glucose sensitizes the kidney to pressure-induced damage 
which is central to early hyperplasia and late hypertrophy of the renal cells 9. This is 
enhanced by ROS generation with upregulation of various vasoactive factors and 
cytokines, which is followed by ECM accumulation 72. Therefore, we tried to identify 
whether this protection could have effects in mRNA expression of vasoactive factors and 
cytokines in vivo. 
We demonstrated that some vasoactive factors such as AGT, VEGF, NO producing 
enzymes eNOS and iNOS were significantly upregulated in diabetic animals after 1 
month of onset of diabetes. These factors are shown to be associated with 
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intraglomerular pressure and increased permeability in the first stages of diabetic 
nephropathy 8. The treatment with maFGF prevented upregulation of eNOS and AGT but 
failed to prevent upregulation of iNOS and VEGF in this first stage. However, after 6 
months of administration of maFGF treatment, prevention of diabetes- induced mRNA 
upregulation of the hypertrophic marker AGT was sustained, indicating prevention of 
hypertrophy from an early stage. These results were supported by significant prevention 
of diabetic-induced increase of kidney weight - tibia length ratio by maFGF treatment 
after 6 months. Additionally, after 6 months of administration, maFGF also prevented 
diabetes- induced downregulation of VEGF and NO producing enzymes eNOS and iNOS 
which are features of advanced DN. Exact reason for such attenuation is not known. It is 
possible that in these later stages the levels of such factors decrease, possibly due to 
endothelial dysfunction causing the arrest of endothelial growth and inducing apoptosis 
8, 9. Treatment with maFGF could partially protect diabetes-induced molecular levels of 
renal damage in the first stages and prevent alteration of these molecular levels at later 
stages.  
These in vivo findings were confirmed by in vitro studies: both, HMVEC and podocytes 
showed significant upregulation in the expression of AGT under high glucose condition, 
which was prevented by maFGF treatment at 48 hours. Some evidence revealed that 
exposing glomerular endothelial cells and podocytes in culture to high glucose activates 
production of AGT 73, 74. AGT is the precursor of angiotensin II (ANG II) and is one of the 
components of the renin-angiotensin system (RAS) which could be locally activated in 
podocytes and endothelial cells by high glucose. The activation of intracellular RAS 
system in these cells is thought to be involved in progression of DN 74. Parallel to this, we 
found that maFGF treatment significantly prevented high glucose- induced down 
regulation of eNOS mRNA expression in both cell types at 48 hours.  In vitro studies done 
by others have evidenced that hyperglycemia- induced ROS production reduces eNOS 
expression and activity in endothelial cells leading to decreased endothelial cell survival 
and endothelial dysfunction 11, 19. Similarly, eNOS deficiency provokes profound effects 
on podocyte integrity and leads to albuminuria 12, 26. These results suggest that 
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treatment with maFGF could protect cellular dysfunction and damage induced by high 
glucose in part through mechanisms involving prevention of AGT and eNOS alteration, 
although further studies need to be done to elucidate whether this prevention is 
secondary of the prevention of ROS production.  
4.1.4 The prevention of functional, biochemical and structural changes in DN by maFGF 
seems to work through a TGFβ-1 independent pathway 
High glucose enhances cellular ROS generation exerting upregulation of various 
vasoactive factors and cytokines, which is followed by ECM accumulation 72. We 
detected the mRNA expression of fibrosis markers TGFβ-1, FN and Col 1α (IV) in both in 
vivo diabetic mouse model after 1 month and 6 months after onset of diabetes, and in 
vitro cultured cell lines exposed to high glucose. We demonstrated up-regulation of 
mRNA expression of these fibrosis-related genes in diabetic animals and in both cell 
types HMVEC and podocytes exposed to high glucose. During the in vivo study maFGF 
showed some preventive effects on alteration of extracellular matrix proteins FN and Col 
1α (IV) exhibited by mRNA and protein expression and confirmed by PAS staining, 
especially after longer administration. However, the treatment failed to prevent the 
induced fibrogenic cytokine TGF-β1. Surprisingly, the in vitro studies showed similar 
results with respect to maFGF failing to prevent the fibrogenic cytokine TGF-β1 in both 
cell types. Additionally, it failed to prevent the high glucose- induced upregulation of the 
ECM proteins FN and Col 1α (IV) in HMVEC, but not in podocytes in which showed 
significant prevention.  According to this, maFGF treatment failed to prevent the 
fibrogenic factor TGF-β1, although partially prevented diabetes-induced upregulation of 
extracellular matrix proteins. TGF-β1 is known to be the main mediator of the 
abnormalities of DN, as it is a key regulator of ECM protein synthesis and responsible for 
apoptosis in podocytes and fibroblasts proliferation 75, 76, 77. The results obtained in this 
study show that diabetes- induced damage and biochemical and structural changes in 
kidneys are attenuated by maFGF and that such process may work through a TGF- β1 
independent pathway 20, 46, 50, 54, 78. Current studies in our lab have shown the 
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involvement of other upstream mediators of FN expression in diabetes 79, 80, 81. The 
vasoactive factor endothelin 1  (ET-1), which is upregulated in DN, mediates expression 
of ECM proteins such as FN via NF-κB and AP-1 (activating protein 1) activation79. 
Furthermore, the transcriptional coactivator p300, which is induced by diabetes in target 
organs including the kidneys, is involved in the regulation of gene expression of 
vasoactive factors and ECM proteins in DN 80, 81. This transcription factor also interacts 
with NF-κB in mediating FN expression. The fact that TGF-β1 mRNA upregulation was 
not prevented by the maFGF treatment but ECM expression was partially prevented 
mainly through prevention of FN protein expression suggest that maFGF may exert its 
prevention through interacting with transcription factors such as the aforementioned 
ones. Further studies to elucidate this mechanism are needed.   
4.1.5 The preventative effect of maFGF treatment in DN probably involves stimulation 
of eNOS activity towards production of NO and stimulation of antiapoptotic genes 
expression such as Bcl-2.  
 The protective effects of maFGF treatment in DN, as comparable to native aFGF, may be 
the result of vasodilation, antioxidant, anti-inflammatory and antiapoptotic functions of 
FGFs. Several studies, including ours, reveal protection of FGFs against oxidative stress in 
different models including diabetic complications 61, 67, 78, ischemia- reperfusion injury 56, 
60 or direct induction of oxidative stress 58, 59. Some mechanisms have been proposed to 
elucidate these pleiotropic effects including the activation of PI3 K/Akt and ERK1/2 
pathways 20, 46, or the implication of FGFs on lipids metabolism 54, 78. With the same 
perspective, some studies reveal the activation of eNOS enzyme and the production of 
NO by FGFs 50-54, linking this effect with the vasodilator and antiapoptotic functions.  
Alternatively, evidence shows that production of superoxide may cause uncoupling of 
eNOS leading to production of superoxide anion rather than NO 15, 20-23 which is known 
to play a key role in vascular homeostasis. Our results demonstrated that maFGF causes 
prevention of oxidative stress in vivo and in vitro, as well as corrects the deficit of eNOS 
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enzyme expression. Therefore, we tried to identify whether maFGF has any effects in NO 
production in vivo and in vitro as indication of eNOS activation in a coupled state.  
We demonstrated that diabetic-induced decrease of NO production was concomitant 
with the down regulation of eNOS enzyme in later stages of DN. The treatment with 
maFGF significantly increased NO production. These findings were confirmed in vitro 
showing that in both cell types HMVEC and podocytes, maFGF significantly restored the 
high-glucose induced decrease production of NO. Furthermore, similar results were 
obtained when these cells were treated with L-NAME, an eNOS inhibitor, showing that 
maFGF similar to aFGF, exerts activation of eNOS in a coupled state. In spite of using L-
NAME NO levels were not completely abolished. Exact reason is not evident. Potential 
explanation may be in the specific system used in this study which showed higher basal 
levels. These results may suggest that some of the beneficial effects of maFGF in DN 
could be through activation of eNOS in a coupled state with subsequent production of 
NO that restores the deficit of NO and therefore preventing cell dysfunction. Moreover, 
maFGF would prevent uncoupled eNOS- induced ROS production (Figure 4.1).  
Interestingly, evidence in support of the importance of high glucose induced- ROS and 
oxidative DNA damage in mediating apoptosis is reflected in our in vitro studies that 
show reduced antiapoptotic- proapoptotic Bcl-2/Bak-1 ratio mRNA expression in HMVEC 
and podocytes exposed to high glucose. Numerous studies show that aFGF and maFGF 
plays a key role in the prevention of cell death 48, 49, 55, 56. The treatment with maFGF 
significantly restored the reduction of Bcl-2/Bak-1 ratio comparable with aFGF. These 
results were confirmed with TUNEL assay in kidney tissues that showed maFGF 
prevention of increased TUNEL positive cells observed in diabetic animals.  Further 
correlation studies could establish an association between the ability of maFGF to 
activate the activity of eNOS towards the production of NO and the preventative effects 
of maFGF against oxidative stress, apoptosis, and subsequent biochemical and structural 
changes, and functional damage prevention. In addition, assessment of effects of maFGF 
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treatment in nitrosative stress is essential since ONOO- formation is potentially a major 
pathway governing NO reactivity 17, 82.  
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Figure 4.1 Scheme depicting proposed mechanism underlying prevention of DN by 
maFGF treatment. High glucose induces increase production of ROS which reacts with 
NO to form the potent oxidizing species peroxynitrite (ONOO-). The oxidation of eNOS 
cofactor BH4 decreases availability which, in addition to the oxidation of eNOS zinc-
thiolate cluster, leads to eNOS uncoupling which produce ROS rather than NO. The 
activation of eNOS in a coupled state by maFGF prevents production of ROS and restores 
NO deficiency. The questions marks indicate further studies that need to be done to 
elucidate the exact mechanism of eNOS activation by maFGF. Other potential pathways 
that may additionally contribute to attenuation of ROS such as prevention of AGT mRNA 
expression need further clarification (Figure adapted from reference # 83). 
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Finally, our findings show that  maFGF prevents 1) functional damage and biochemical 
and structural changes in DN, 2) oxidative stress and oxidative DNA damage in DN, 3) 
diabetic-induced apoptosis in kidneys and high glucose-induced apoptosis in HMVEC and 
podocytes, 4) deficient  NO production in kidney tissues of diabetic animals and in 
MHVEC and podocytes under high glucose conditions. These results suggest that the 
preventative effect of maFGF treatment in DN is probably mediated by attenuation of 
renal oxidative stress, stimulation of eNOS expression and activity in a coupled state that 
leads to increased levels of NO production and stimulation of expression of 
antiapoptotic genes such as Bcl-2. It is important to emphasize that, in these studies, 
maFGF showed a similar anti-oxidative and antiapoptotic capacity to native aFGF 
underscoring the possible advantage of maFGF for clinical implications. maFGF does not 
have mitogenic action as demonstrated before 55, 57 and therefore would lack oncogenic 
effect compared to the native aFGF. These results are also concomitant with previous 
studies done with maFGF and its effects in diabetic cardiomyopathy 61. This indicates a 
potential therapeutic role of maFGF in DN. 
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4.2 Future directions 
We have shown the protective effects of maFGF in DN in a type 1 diabetic mouse 
model and in high glucose-induced changes of two cells types present in the kidneys, 
namely: HMVEC and podocytes, which are part of the integrative filtration barrier. To 
further establish the protective effects of maFGF in DN, the assessment of the role of 
maFGF in inflammation and lipid metabolism in DN would be suggested. Similarly, the 
use of a type 2 diabetic mouse model could be of interest to study the involvement of 
FGF in DN- induced changes in the context of insulin resistance. Some studies have 
previously shown that FGF21 and FGF1 play an important role in glucose homeostasis as 
insulin sensitizers 75, 78. Hence, enhancing its benefits as a potential therapy to avoid 
diabetic complications would be useful.  
In vitro studies with other cell types present in the kidneys could also be considered. 
Advance identification of the effects of maFGF in the pathophysiology of diabetic 
glomerulopathy would require studies with mesangial cells which are also part of the 
filtration barrier 79. Additionally, the same approach for the study of epithelial tubular 
cells and fibroblasts is recommended since high glucose- induced signalling 
abnormalities in these cells probably contributes to progressive fibrosis and can induce 
epithelial- to- mesenchymal transition in DN 12.  
FGFs are pleiotropic peptides and can exert a variety of actions in the cells. Identification 
of other activated downstream pathways of maFGF or interaction with other cellular 
molecules in the regulation of high-glucose induced cellular alterations would be 
necessary to uncover new mechanisms. Finally, in an attempt to further understand the 
involvement of native aFGF, mechanisms regulating its production may further need to 
be clarified. In any chronic diseases, possible impact of epigenetic mechanisms, which 
may regulate such expressions, may need further experiments. It is important to point 
out that in some recent studies intricate relationship of FGF with microRNAs and 
epigenetic mechanisms have been demonstrated 84, 85, 86, 87. A better understanding of 
such mechanisms will help open up the possibility of using maFGF in DN or other chronic 
diabetic complications. 
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